BIO-TECHNE Corp Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain
BIO-TECHNE Corp (TECH) reported Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain of $0 for the 12-month period ending 2016-06-30, per its 10-K filed 2016-08-29.
Discontinued › Income Statement › Other Income
us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain · last filed 2017-09-07
- BIO-TECHNE Corp business combination, step acquisition, equity interest in acquiree, remeasurement gain for the quarter ending 2016-03-31 was $0.00.
- BIO-TECHNE Corp business combination, step acquisition, equity interest in acquiree, remeasurement gain for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- BIO-TECHNE Corp business combination, step acquisition, equity interest in acquiree, remeasurement gain for the quarter ending 2015-06-30 was $0.00.
- BIO-TECHNE Corp business combination, step acquisition, equity interest in acquiree, remeasurement gain for the quarter ending 2015-03-31 was $0.00.
- BIO-TECHNE Corp business combination, step acquisition, equity interest in acquiree, remeasurement gain for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- BIO-TECHNE Corp business combination, step acquisition, equity interest in acquiree, remeasurement gain for fiscal 2015 was $8.30M.
- BIO-TECHNE Corp business combination, step acquisition, equity interest in acquiree, remeasurement gain for fiscal 2014 was $0.00.
- BIO-TECHNE Corp business combination, step acquisition, equity interest in acquiree, remeasurement gain for fiscal 2013 was $0.00.
| Period end | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain 3 month | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain 6 month | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain 9 month | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain 12 month |
|---|---|---|---|---|
| 2016-06-30 | $0.00 10-K · filed 2016-08-29 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | $0.00 derived: sum of 2 quarters · filed 2016-05-10 | ||
| 2015-12-31 | $0.00 10-Q · filed 2016-02-09 | $0.00 10-Q · filed 2016-02-09 | ||
| 2015-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $0.00 derived: sum of 2 quarters · filed 2017-09-07 | $8.30M derived: sum of 3 quarters · filed 2017-09-07 | $8.30M 10-K · filed 2017-09-07 |
| 2015-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10 | $8.30M derived: sum of 2 quarters · filed 2016-05-10 | $8.30M 10-Q · filed 2016-05-10 | |
| 2014-12-31 | $8.30M 10-Q · filed 2016-02-09 | $8.30M 10-Q · filed 2016-02-09 | ||
| 2014-06-30 | $0.00 10-K · filed 2016-08-29 | |||
| 2013-12-31 | $0.00 10-Q · filed 2015-02-09 | $0.00 10-Q · filed 2015-02-09 | ||
| 2013-06-30 | $0.00 10-K · filed 2015-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |